Cetera Trust Company N.A Has $1.46 Million Stock Holdings in Elevance Health, Inc. (NYSE:ELV)

Cetera Trust Company N.A lowered its holdings in Elevance Health, Inc. (NYSE:ELV) by 15.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,961 shares of the company’s stock after selling 725 shares during the quarter. Cetera Trust Company N.A’s holdings in Elevance Health were worth $1,461,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Raelipskie Partnership bought a new position in Elevance Health in the 3rd quarter valued at $26,000. PSI Advisors LLC bought a new position in shares of Elevance Health in the third quarter worth about $27,000. Eastern Bank bought a new stake in shares of Elevance Health during the third quarter valued at approximately $31,000. Dunhill Financial LLC raised its position in Elevance Health by 57.8% in the 3rd quarter. Dunhill Financial LLC now owns 71 shares of the company’s stock worth $37,000 after purchasing an additional 26 shares during the last quarter. Finally, Peterson Financial Group Inc. bought a new position in Elevance Health in the 3rd quarter valued at $44,000. 89.24% of the stock is currently owned by institutional investors.

Elevance Health Stock Performance

NYSE:ELV opened at $383.90 on Wednesday. The company has a market cap of $89.03 billion, a price-to-earnings ratio of 14.03, a PEG ratio of 1.09 and a beta of 0.84. The stock has a fifty day moving average price of $386.73 and a 200-day moving average price of $464.16. Elevance Health, Inc. has a fifty-two week low of $362.21 and a fifty-two week high of $567.26. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.50 and a current ratio of 1.50.

Wall Street Analysts Forecast Growth

ELV has been the subject of a number of research reports. StockNews.com upgraded Elevance Health from a “hold” rating to a “buy” rating in a research report on Friday, January 17th. Barclays dropped their target price on shares of Elevance Health from $622.00 to $501.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Morgan Stanley decreased their price objective on Elevance Health from $643.00 to $551.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. Cantor Fitzgerald decreased their target price on Elevance Health from $600.00 to $485.00 and set an “overweight” rating for the company in a research report on Friday, October 18th. Finally, Raymond James set a $485.00 price objective on shares of Elevance Health in a report on Friday, October 18th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Elevance Health currently has a consensus rating of “Moderate Buy” and an average price target of $524.87.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.